Pfizer bivalent BA.4/5- COVID-19 vaccine

Australia’s active vaccine safety system

COVID-19 vaccines

Data on this page show the responses of all individuals who received a Pfizer bivalent BA.4/5 COVID-19 vaccine and completed an AusVaxSafety survey sent on day 3 after vaccination. These data provide you with a profile of what to expect in the days following your Pfizer bivalent BA.4/5 COVID-19 vaccination and can assist when planning for your COVID-19 vaccination.

AusVaxSafety's active vaccine safety surveillance system complements the TGA's enhanced safety surveillance activities. Find out more about how the TGA monitors the safety of COVID-19 vaccines and how you can report side effects on the TGA website.

Links to further information on the expected profile for Pfizer bivalent BA.4/5 COVID-19 vaccine are available below:

AusVaxSafety will continue to closely monitor the safety data of COVID-19 vaccines in use in Australia in conjunction with the TGA.

Last updated March 2024

COVID-19 vaccines

Shingrix® vaccine safety data now available

AusVaxSafety receives funding
from the Australian Government

NCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433 | Fax (612) 9845 1418 | ABN 53 188 579 090

We acknowledge that the National Centre for Immunisation Research and Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.

Our website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.

We acknowledge that the National Centre for Immunisation Research & Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.

Pfizer bivalent BA.4/5- COVID-19 vaccine

COVID-19 vaccines

COVID-19 vaccines

News & events

AusVaxSafety commences routine surveillance of 2024 seasonal influenza vaccines

Vaccine safety in Australia AusVaxSafety summary report now available

What to expect in the days after your XBB.1.5 COVID-19 vaccine

Shingrix® vaccine safety data now available

Subscribe to our newsletter for immunisation professionals

Subscribe to our newsletter for immunisation professionals